Visions/iStock via Getty Images Tirzepatide, currently marketed by Eli Lilly ( NYSE: LLY ) as Mounjaro and Zepbound for, respectively, diabetes and weight loss, met its main goal in a phase 3 program examining the drug as a treatment for obstructive sleep apnea. In two trials, tirzepatide led to a mean reduction of up to 62.8% on the apnea-hypopnea index ("AHI") -- about 30 fewer events of an individual's breathing restricted per hour of sleep versus placebo.
A secondary endpoint in the SURMOUNT-OSA program showed that 43% in the first study and 51.5% in the second of participants in the treatment arms achieved disease resolution . Tirzepatide has U.
S. FDA Fast Track status for treatment of moderate-to-severe OSA with obesity. The drugmaker has already submitted an application for the additional indication to the agency with a decision coming as soon as the end of the year.
More on Eli Lilly Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Hims & Hers defended at BofA as Lilly fights compounded GLP-1s Eli Lilly ramps up efforts against fake weight loss drugs.
